Thymoquinone: A Promising Natural Compound with Potential Benefits for COVID-19 Prevention and Cure

被引:45
作者
Badary, Osama A. [1 ,2 ]
Hamza, Marwa S. [1 ]
Tikamdas, Rajiv [1 ]
机构
[1] British Univ Egypt, Fac Pharm, Clin Pharm Practice Dept, POB 43, Cairo 11837, Egypt
[2] Ain Shams Univ, Fac Pharm, Clin Pharm Dept, Cairo, Egypt
来源
DRUG DESIGN DEVELOPMENT AND THERAPY | 2021年 / 15卷
关键词
thymoquinone; COVID-19; natural; therapeutic benefits; NIGELLA-SATIVA L; NANOSTRUCTURED LIPID CARRIER; OXIDATIVE STRESS; ISCHEMIA-REPERFUSION; GENE-EXPRESSION; CONSTITUENT THYMOQUINONE; ORAL BIOAVAILABILITY; MAJOR CONSTITUENT; SIGNALING PATHWAY; ACTIVE COMPONENT;
D O I
10.2147/DDDT.S308863
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
COVID-19 has caused a major global health crisis, as excessive inflammation, oxidation, and exaggerated immune response in some sufferers can lead to a condition known as cytokine storm, which may progress to acute respiratory distress syndrome (ARDs), which can be fatal. So far, few effective drugs have emerged to assist in the treatment of patients with COVID-19, though some herbal medicine candidates may assist in the fight against COVID-19 deaths. Thymoquinone (TQ), the main active ingredient of black seed oil, possesses antioxidant, anti-inflammatory, antiviral, antimicrobial, immuno-modulatory and anticoagulant activities. TQ also increases the activity and number of cytokine suppressors, lymphocytes, natural killer cells, and macrophages, and it has demon-strated antiviral potential against a number of viruses, including murine cytomegalovirus, Epstein-Barr virus, hepatitis C virus, human immunodeficiency virus, and other corona-viruses. Recently, TQ has demonstrated notable antiviral activity against a SARSCoV-2 strain isolated from Egyptian patients and, interestingly, molecular docking studies have also shown that TQ could potentially inhibit COVID-19 development through binding to the receptor-binding domain on the spike and envelope proteins of SARS-CoV-2, which may hinder virus entry into the host cell and inhibit its ion channel and pore forming activity. Other studies have shown that TQ may have an inhibitory effect on SARS CoV2 proteases, which could diminish viral replication, and it has also demonstrated good antagonism to angiotensin-converting enzyme 2 receptors, allowing it to interfere with virus uptake into the host cell. Several studies have also noted its potential protective capability against numerous chronic diseases and conditions, including diabetes, hypertension, dyslipidemia, asthma, renal dysfunction and malignancy. TQ has recently been tested in clinical trials for the treatment of several different diseases, and this review thus aims to highlight the potential therapeutic effects of TQ in the context of the COVID-19 pandemic.
引用
收藏
页码:1819 / 1833
页数:15
相关论文
共 203 条
  • [1] The Effect of Route of Administration in Thymoquinone Toxicity in Male and Female Rats
    AbuKhader, M. M.
    [J]. INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 74 (03) : 195 - 200
  • [2] Protective effects of thymoquinone on D-galactose and aluminum chloride induced neurotoxicity in rats: biochemical, histological and behavioral changes
    Abulfadl, Yasmin S.
    El-Maraghy, Nabila N.
    Ahmed, Amany Ali Eissa
    Nofal, Shahira
    Badary, Osama A.
    [J]. NEUROLOGICAL RESEARCH, 2018, 40 (04) : 324 - 333
  • [3] Aggarwal S, 1999, J IMMUNOL, V162, P2154
  • [4] Ahmad Aftab, 2013, Asian Pacific Journal of Tropical Biomedicine, V3, P337, DOI 10.1016/S2221-1691(13)60075-1
  • [5] Covid-19 and thymoquinone: Connecting the dots
    Ahmad, Ajaz
    Rehman, Muneeb U.
    Ahmad, Parvaiz
    Alkharfy, Khalid M.
    [J]. PHYTOTHERAPY RESEARCH, 2020, 34 (11) : 2786 - 2789
  • [6] Thymoquinone treatment modulates the Nrf2/HO-1 signaling pathway and abrogates the inflammatory response in an animal model of lung fibrosis
    Ahmad, Ajaz
    Alkharfy, Khalid M.
    Jan, Basit Latief
    Ahad, Abdul
    Ansari, Mushtaq Ahmad
    Al-Jenoobi, Fahad I.
    Raish, Mohammad
    [J]. EXPERIMENTAL LUNG RESEARCH, 2020, 46 (3-4) : 53 - 63
  • [7] Ahmed N, 2021, J ADV BIOTECHNOL EXP, V4, P133, DOI [10.5455/jabet.2021.d114, DOI 10.5455/JABET.2021.D114]
  • [8] Al-Ali Amein, 2008, J Ayub Med Coll Abbottabad, V20, P25
  • [9] Al-Shabanah OA, 1998, J EXP CLIN CANC RES, V17, P193
  • [10] NITRIC OXIDE PATHWAY AS A POTENTIAL THERAPEUTIC TARGET IN COVID-19
    Alkharfy, Khalid M.
    Rehman, Muneeb U.
    Ahmad, Ajaz
    [J]. FARMACIA, 2020, 68 (06) : 966 - 969